- Home
- BPOPM vs CERT Comparison
BPOPM vs CERT Comparison
Compare BPOPM & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
BPOPM
Popular Inc. Popular Capital Trust II - 6.125% Cumulative Monthly Income Trust Preferred Securities
Current Price
Company Overview
Basic Information| Metric | BPOPM | CERT |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 1.4B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BPOPM | CERT |
|---|---|---|
| Price | $25.20 | $9.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | N/A | ★ 2.4M |
| Earning Date | N/A | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $415,551,000.00 |
| Revenue This Year | N/A | $10.82 |
| Revenue Next Year | N/A | $6.77 |
| P/E Ratio | ★ N/A | $134.09 |
| Revenue Growth | N/A | ★ 11.47 |
| 52 Week Low | N/A | $8.03 |
| 52 Week High | N/A | $15.69 |
Technical Indicators
Market Signals| Indicator | BPOPM | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 50.46 | 47.95 |
| Support Level | $24.95 | $8.42 |
| Resistance Level | $25.48 | $9.17 |
| Average True Range (ATR) | 0.17 | 0.39 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 49.23 | 53.60 |
Price Performance
Historical ComparisonAbout BPOPM Popular Inc. Popular Capital Trust II - 6.125% Cumulative Monthly Income Trust Preferred Securities
Popular Capital Trust II is a statutory trust. It is engaged in issuing capital securities.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.